. _							Sheet	1 1	of 1
Form F	TO-1449 8-83)		PATENT & TAX EMARK OFFICE				APPLICATION NO. 10/532,792		
INFORMATION DISCLOSURE STATEMENT								•	
(Use several sheets if the essing)					APPLICANT				
50					Kusuki NISHIOKA				
JUL 2 5 2005 125					FILING DATE April 25, 2005		GROUP		
		T	U.S.	PATI	ENT DOCL	IMENTS		· · · · · · · · · · · · · · · · · · ·	
EXAMINER INITIAL			DOCUMENT NUMBER		DATE	NAME	NAME		SUB CLASS
AS		1	US 6,165,515	12/26/2000		Matsuyama et al.	uyama et al.		
		l	<u> </u>	GN P	ATENT DO	DCUMENTS		ll	
		DOCUMENT NUMBER		DATE		COUNTRY		CLASS	SUB CLASS
A-	5	2	JP B 63-39572 w/abst	08/	05/1988	Japan			
		3	JP B 2594222 w/abst	12/19/1996		Japan			
		4	JP A 53-101515 w/abst	09/	05/1978	Japan			
		5	JP A 55-87724 w/abst	07/02/1980		Japan			
		6	JP A 1-265028 w/abst	10/23/1989		Јарап			
		7	JP A 1-319422 w/abst	12/25/1989		Japan			
		8	JP A 2-28119 w/abst	01/30/1990		Japan			
		9	JP A 7-97336 w/abst	04/	11/1995	Japan			· · · · · ·
		10 JP A 8-291077 w/abst		11/0	05/1996	Japan			· / · · · ·
		11 JP A 10-194978 w/abst		07/28/1998		Japan			
		12	12 JP A 11-80005 w/abst		03/23/1999 Japan		•		
		13	JP A 11-139977 w/abst	05/2	/25/1999 Japan				
		14	JP A 2000-336034 w/abst	12/0	05/2000	Japan			•
		15	JP A 2000-16942 w/abst	01/	18/2000	Japan .			
		16	EP 0 852 950 B1	07/	15/1998	Europe			
		17	WO 01/68643 A2 w/abst.	09/2	20/2001	WIPO			
		18	EP 0 348 353 A2	12/2	27/1989	Europe			
		19	EP 0 645142 A1	03/2	29/1995	Еигоре			
		20	EP 0 916 344 A2	05/	19/1999	Еигоре			
		21	EP 1 038 529 A2	09/2	27/2000	Europe			_
		22	EP 0 953 352 A1	11/0	03/1999	Europe			· ·
	/	23	JP A 2001-58950 w/abst	03/0	06/2001	Japan			
			T			Title, Date, Pertinent Pages, etc.)			
124 "Drugs in Japan", ethical Drugs[(25th edition), edited by Japan Pharmaceutical Information Center: published by Jino, Inc.									

(2002)], pages 2379 - 2381, with concise explanation.

A 25 "Rheumatism", 2003 April, Vol. 4, No. 2, page 331, W 51-6-O/P, with translation.

EXAMINER

DATE CONSIDERED

1/27/06

Examiner:

Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.